These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3098416)

  • 21. 5-OH-dopa, product of and substrate for tyrosinase.
    Agrup G; Rorsman H; Rosengren E
    Acta Derm Venereol; 1982; 62(5):371-76. PubMed ID: 6183884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An improved HPLC-electrochemical detection method for measuring brain levels of 5-S-cysteinyldopamine, 5-S-cysteinyl-3,4-dihydroxyphenylalanine, and 5-S-cysteinyl-3,4-dihydroxyphenylacetic acid.
    Fornstedt B; Bergh I; Rosengren E; Carlsson A
    J Neurochem; 1990 Feb; 54(2):578-86. PubMed ID: 2105377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [High-performance liquid chromatographic determination of urinary 5-S, 2-S-, 6-S-cysteinyldopa and 2,5-S,S-dicysteinyldopa (author's transl)].
    Morishima T; Saito M; Fujita M; Fukada E; Hanawa S
    Nihon Hifuka Gakkai Zasshi; 1982 Jan; 92(1):53-6. PubMed ID: 6804671
    [No Abstract]   [Full Text] [Related]  

  • 24. Automated high-performance liquid chromatographic determination of 5-S-cysteinyl-3,4-dihydroxyphenylalanine in urine.
    Kågedal B; Källberg M; Arstrand K; Hansson C
    J Chromatogr; 1989 Jul; 473(2):359-70. PubMed ID: 2504759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective toxicity of 5-S-cysteinyldopa, a melanin precursor, to tumor cells in vitro and in vivo.
    Fujita K; Ito S; Inoue S; Yamamoto Y; Takeuchi J; Shamoto M; Nagatsu T
    Cancer Res; 1980 Jul; 40(7):2543-6. PubMed ID: 6771000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-S-Cysteinyldopa in ganglion stellatum.
    Fehling C; Hansson C; Poulsen J; Rorsman H; Rosengren E
    J Neural Transm; 1981; 52(3):251-7. PubMed ID: 6796651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species.
    Fornstedt B; Rosengren E; Carlsson A
    Neuropharmacology; 1986 Apr; 25(4):451-4. PubMed ID: 3086766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Contents of cysteinyldopa isomers and DOPA in lesions of malignant melanoma (author's transl)].
    Morishima T; Saito M; Fujita M; Fukada E; Nagashima N; Hanawa S
    Nihon Hifuka Gakkai Zasshi; 1982 Feb; 92(2):157-9. PubMed ID: 6806514
    [No Abstract]   [Full Text] [Related]  

  • 29. Protein-bound dopa and 5-S-cysteinyldopa in non-melanogenic tissues.
    Ito S; Jimbow K; Kato T; Kiyota M; Fujita K
    Acta Derm Venereol; 1983; 63(6):463-7. PubMed ID: 6198833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formation of glutathionedopa in albino rats after DOPA injection.
    Fehling C; Hansson C; Poulsen J; Rorsman H; Rosengren E
    Acta Derm Venereol; 1981; 61(4):339-42. PubMed ID: 6173990
    [No Abstract]   [Full Text] [Related]  

  • 31. 5-S-cysteinyldopa and trichochromes in red feathers.
    Agrup G; Hansson C; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1978; 58(3):269-70. PubMed ID: 78644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of total body photography on biopsy rate in patients from a pigmented lesion clinic.
    Risser J; Pressley Z; Veledar E; Washington C; Chen SC
    J Am Acad Dermatol; 2007 Sep; 57(3):428-34. PubMed ID: 17624623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solitary small active junctional nevi in juvenile patients.
    Eng AM
    Arch Dermatol; 1983 Jan; 119(1):35-8. PubMed ID: 6849562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of urinary 5-S-cysteinyldopa by high-performance liquid chromatography.
    Kågedal B; Pettersson A
    J Chromatogr; 1983 Feb; 272(2):287-97. PubMed ID: 6403561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new concept of melanocytic neoplasia pathogenesis based on the phenotype of common acquired nevi.
    Batistatou A; Zioga A; Panelos J; Massi D; Agnantis NJ; Charalabopoulos K
    Med Hypotheses; 2007; 69(6):1334-9. PubMed ID: 17459602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Free and bound 5-S-cysteinyldopa and dopa in human malignant melanomas.
    Agrup G; Hansson C; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1978; 58(3):270-2. PubMed ID: 78645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melanocytic nevi with features of Spitz nevi and Clark's/dysplastic nevi ("Spark's" nevi).
    Ko CJ; McNiff JM; Glusac EJ
    J Cutan Pathol; 2009 Oct; 36(10):1063-8. PubMed ID: 19187111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects.
    Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A
    J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative frequency of solitary melanocytic lesions of the oral mucosa.
    Buchner A; Merrell PW; Carpenter WM
    J Oral Pathol Med; 2004 Oct; 33(9):550-7. PubMed ID: 15357676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dysplastic melanocytic nevi and prognostically indeterminate nevomelanomatoid proliferations.
    Kim JC; Murphy GF
    Clin Lab Med; 2000 Dec; 20(4):691-712. PubMed ID: 11221510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.